cancer is a major global problem and is the second leading cause of mortality in the developed countries.resistance to current chemotherapeutics and high incidence of adverse effects are the two principal reasons for developing new anticancer agents. phenylacetamide derivatives can act as potential anticancer agents. synthesis and screening of 2-(4-fluorophenyl)-n-phenylacetamide derivatives in...

INTRODUCTION Adjuvant imatinib improves recurrence-free survival of patients following resection of primary KIT-positive gastrointestinal stromal tumors. However, it is unknown whether patients who previously received adjuvant imatinib therapy will respond to imatinib rechallenge as treatment for recurrent disease. Here we present the first report documenting the benefits of imatinib rechalleng...

Background Imatinib is used in chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. The major aim of this study was to investigate the effects of Imatinib on male fertility in Wistar rats. MaterialsAndMethods Three groups of rats were gavaged with 6, 9, and 12 mg/kg Imatinib dissolved in dH2O for 30 consecutive days. On days 7, 14 and 3...

With no routine accessible medicine intervention for spinal cord damage, there is a demand for more remedial candidates. However, for Imatinib to have translational price, it requires to have encouraged obliging effects with delayed start of treatment, as well. Serum levels of 3 chemokines/ cytokines, MIP-3α, MCP-1, and GRO/ KC (IL-8), to raise over time with Imatinib treatment and to be ...

Recent data suggest that the role of CYP3A4 in imatinib metabolism is smaller than presumed. This study aimed to evaluate the quantitative importance of different cytochrome P450 (P450) enzymes in imatinib pharmacokinetics. First, the metabolism of imatinib was investigated using recombinant P450 enzymes and human liver microsomes with P450 isoform-selective inhibitors. Thereafter, an in silico...

BACKGROUND Imatinib has been found to be effective in the treatment of patients with gastrointestinal stromal tumors (GIST). We sought to evaluate the clinical outcome of imatinib interruption in GIST patients who had achieved stable disease (SD) or showed better response to imatinib therapy. METHODS From July 2001 to December 2004, we prospectively collected clinical data from 62 consecutive...

BACKGROUND/AIMS The treatment of chronic myeloid leukemia (CML) has achieved impressive success since the development of the Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate. Nevertheless, resistance to imatinib has been observed, and a substantial number of patients need alternative treatment strategies. METHODS We have evaluated the effects of deferasirox, an orally active iron chelator...

BACKGROUND Imatinib is actively transported into cells by the organic cation transporter (OCT1), encoded by SLC22A1. As a result, the expression of SLC22A1 is considered a prognostic marker for treatment with imatinib in patients with chronic myeloid leukemia (CML). Although limited, there is conflicting evidence indicating that imatinib may affect the expression of SLC22A1. However, thus far, ...

background: imatinib is used in chronic myelogenous leukemia (cml), gastrointestinal stromal tumors (gists) and a number of other malignancies. the major aim of this study was to investigate the effects of imatinib on male fertility in wistar rats. materials and methods: three groups of rats were gavaged with 6, 9, and 12 mg/kg imatinib dissolved in dh2o for 30 consecutive days. on days 7, 14 a...

background: imatinib mesylate, a small-molecular analog of adenosine triphosphate (atp) that potently inhibits tyrosine kinase activities of bcr–abl, pdgfr-β, pdgfr-α, c-fms, arg and c-kit, is one of the novel molecularly targeted drugs being introduced into cancer therapy. we tested the effect of imatinib on the ovarian histological structure and the concentration of estrogen and progesterone,...